Literature DB >> 856605

Protein binding of salicylate and quinidine in plasma from patients with renal failure, chronic liver disease and chronic respiratory insufficiency.

M Pérez-Mateo, S Erill.   

Abstract

The plasma protein binding of a representative acidic drug, salicylate, and a representative basic drug, quinidine, has been studied in patients with several diseases that are sometimes associated with uraemia or a change in serum albumin level. Decreased plasma protein binding of salicylate was observed in plasma from patients with uraemia and liver disease. Low albumin levels in these patients could only account inpart for the decreased binding. On the other hand, salicylate binding to plasma proteins appeared to be increased in patients with hypoxia. Decreased plasma protein binding of quinidine was observed in some patients with uraemia and in the majority of patients with liver disease.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 856605     DOI: 10.1007/BF00606415

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  23 in total

1.  The protein binding of some drugs in plasma from patients with alcoholic liver disease.

Authors:  M Affrime; M M Reidenberg
Journal:  Eur J Clin Pharmacol       Date:  1975-04-04       Impact factor: 2.953

2.  Decreased drug binding by serum albumin during renal failure.

Authors:  D S Campion
Journal:  Toxicol Appl Pharmacol       Date:  1973-07       Impact factor: 4.219

3.  Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function.

Authors:  M M Reidenberg; I Odar-Cederlöf; C von Bahr; O Borgå; F Sjöqvist
Journal:  N Engl J Med       Date:  1971-07-29       Impact factor: 91.245

4.  Abnormal pharmacokinetics of phenytoin in a patient with uraemia.

Authors:  I Odar-Cederlöf; P Lunde; F Sjöqvist
Journal:  Lancet       Date:  1970-10-17       Impact factor: 79.321

5.  Influence of disease on binding of drugs to plasma proteins.

Authors:  M M Reidenberg; M Affrime
Journal:  Ann N Y Acad Sci       Date:  1973-11-26       Impact factor: 5.691

6.  Protein binding of drugs in plasma from patients with acute renal failure.

Authors:  F Andreasen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1973

7.  The effect of disease, drugs, and dilution on the binding of sulfonamides in human plasma.

Authors:  A H Anton
Journal:  Clin Pharmacol Ther       Date:  1968 Sep-Oct       Impact factor: 6.875

8.  Altered protein binding of diphenylhydamtoin in uremic plasma.

Authors:  M R Blum; S Riegelman; C E Becker
Journal:  N Engl J Med       Date:  1972-01-13       Impact factor: 91.245

9.  Increased binding of quinidine to serum albumin and lipoproteins in anuric rats.

Authors:  O G Nilsen; D Fremstad; S Jacobsen
Journal:  Eur J Pharmacol       Date:  1975-08       Impact factor: 4.432

10.  Kinetics of salicylate elimination by anephric patients.

Authors:  D T Lowenthal; W A Briggs; G Levy
Journal:  J Clin Invest       Date:  1974-11       Impact factor: 14.808

View more
  11 in total

Review 1.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

2.  Pharmacokinetics of quinidine in male patients. A population analysis.

Authors:  C N Verme; T M Ludden; W A Clementi; S C Harris
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

Review 3.  Pulmonary disease and drug kinetics.

Authors:  P du Souich; A J McLean; D Lalka; S Erill; M Gibaldi
Journal:  Clin Pharmacokinet       Date:  1978 Jul-Aug       Impact factor: 6.447

Review 4.  Disease-induced changes in the plasma binding of basic drugs.

Authors:  K M Piafsky
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

5.  Alteration of drug-protein binding in renal disease.

Authors:  M M Reidenberg; D E Drayer
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

6.  Altered quinidine disposition in a patient with chronic active hepatitis.

Authors:  J R Powell; R Okada; K A Conrad; T W Guentert; S Riegelman
Journal:  Postgrad Med J       Date:  1982-02       Impact factor: 2.401

7.  Plasma protein binding of azapropazone in patients with kidney and liver disease.

Authors:  E Jähnchen; K J Blanck; K H Breuing; H J Gilfrich; T Meinertz; D Trenk
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

8.  Iotroxamide studies in man--plasma binding, renal and biliary excretion studies in jaundiced and anicteric patients.

Authors:  J Doran; W Vennart; C R Richmond; G D Bell
Journal:  Br J Clin Pharmacol       Date:  1978-10       Impact factor: 4.335

Review 9.  Clinical pharmacokinetics of quinidine.

Authors:  H R Ochs; D J Greenblatt; E Woo
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

10.  Decrease of in vitro serum protein binding of salicylate in rheumatoid arthritis.

Authors:  P Netter; C Monot; M C Stalars; J M Mur; R J Royer; G Faure; J Pourel; J Martin; A Gaucher
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Apr-Jun       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.